Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8168666 | 0.83 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL8816520 | 0.80 | SMYD2 (0.34) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL22577716 | 0.80 | SMYD2 (0.34) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL18640763 | 0.80 | SMYD2 (0.34) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL14601099 | 0.79 | SMYD2 (0.34) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL6443627 | 0.77 | SMYD2 (0.33) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL8027742 | 0.77 | SMYD2 (0.33) | SMYD2CYP3A4HTTSMN1; SMN2KDM4E | |
| SCHEMBL2955809 | 0.77 | SMYD2 (0.33) | SMYD2CYP3A4HTTSMN1; SMN2KDM4E | |
| SCHEMBL2415835 | 0.77 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL1504056 | 0.77 | CYP2C9 (0.40) | SMYD2CYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168652-B2 | Inhibitors of AKT activity | MERCK SHARP & DOHME CORP. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20110319443-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319443-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CD, PIK3CA, PIK3CG | SMYD2 2492/4885CYP3A4 3185/4885HTT 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.